Evidence map›Paper›PMID 42665406›Full record

ReviewIn vivo (Athens, Greece)

Plexiform Fibrohistiocytic Tumor: An Updated Review.

Jun Nishio, Kaori Koga, Mikiko Aoki

Abstract readReview
In one paragraph

Review in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jun NishioSection of Orthopaedic Surgery, Department of Medicine, Fukuoka Dental College, Fukuoka, Japan; nishio@fdcnet.ac.jp.
Kaori KogaDepartment of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Mikiko AokiDepartment of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plexiform fibrohistiocytic tumor (PFHT) is a rare locally aggressive and rarely metastasizing mesenchymal neoplasm that most commonly arises in the upper extremities of children and young adults. It typically presents as a small, slow-growing, painless, dermal or subcutaneous mass. Magnetic resonance imaging (MRI) often reveals a plaque-like or infiltrative lesion with intermediate signal intensity on T1-weighted sequences and high signal intensity on T2-weighted sequences. Contrast-enhanced MRI demonstrates moderate or avid enhancement. Histologically, PFHT is characterized by a multinodular or plexiform proliferation of a variable admixture of histiocyte-like cells, osteoclast-like giant cells and elongated spindle cells. Immunohistochemically, the histiocyte-like and osteoclast-like giant cells express CD68, CD163 and CD11c, whereas the spindle cells are focally positive for smooth muscle actin. Most notably, cyclin D1 immunostaining demonstrates nuclear expression in the histiocyte-like and osteoclast-like giant cells as well as spindle cells. Wide local excision with long-term follow-up is generally considered optimal management for conventional cases. This review provides an updated overview of the clinical, radiological, histological, immunohistochemical, cytogenetic and molecular genetic features of PFHT and discusses the differential diagnosis of this enigmatic neoplasm.

Indexed as

NeoplasmsBiomarkers, TumorDiagnosis, DifferentialHumansImmunohistochemistryMagnetic Resonance ImagingBiomarkers, Tumorcellular neurothekeomagiant cell tumor of soft tissueosteoclast-like giant cellsPlexiform fibrohistiocytic tumorplexiform myofibroblastomareview

Identifiers

PMID42665406
PMCPMC13531122

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.